Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Year: 2021
TG4050, First positive clinical data from Phase I clinical trials
link to webcast
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
annonceHomeUS
TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)
Regulated information
Monthly information on shares outstanding and voting rights (in French) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Share buyback program (in French) Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 24 mai 2016 Liquidity contract related information Implementation of the liquidity agreement Half-year report… Continue reading Regulated information
annonce substitut
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video
annonce
One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en
Transgene reports business update and Q3 2021 financial position
20211104 – Transgene – Q3 Financial update EN
Management committee
Management committee Chairman and Chief Executive Officer (CEO) VP, Pharmaceutical Operations & Qualified Pharmacist Chief Scientific Officer (CSO) VP Medical Affairs & Chief Medical Officer (CMO) VP, General Counsel & Corporate Secretary Chief Financial Officer (CFO) Human Resources Director Chief Technical Officer (CTO) VP, Chief Business Officer